News story

Joint MHRA and DIA training: Excellence in Pharmacovigilance

1 to 5 February 2016: This 5-day course will cover European clinical pre and post-marketing safety regulatory requirements.

Excellence in Pharmacovigilance: Clinical Trials and Post-Marketing

About the training

As well as providing a firm grounding on key aspects of global and European clinical pre-and-post-marketing safety regulatory requirements, the course covers updates on pharmacovigilance legislation. It also covers the latest news on the international harmonisation and standardisation activities in pharmacovigilance.

See more information about the course and register .

The key topics include:

  • definitions and methods in pharmacovigilance
  • regulatory aspects in pharmacovigilance and practical examples
  • diagnosis and management of adverse drug reactions
  • signal detection and signal management
  • risk management

Who should attend

The course, delivered by the Medicines and Healthcare products Regulatory Agency (MHRA) and Develop Innovate Advance (DIA), is for professionals involved in pharmacovigilance and qualified persons for pharmacovigilance (EU QPPV) as well as those involved in:

  • clinical research, regulatory affairs, risk management
  • medical product safety assessment
  • data analysis, epidemiology, labelling
  • quality assurance, compliance, medical information


Date and location

1 to 5 February 2016

Holiday Inn London - Regent's Park
Carburton Street

CPD credits

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom has accredited this training course with 32 CPD credits.

The Swiss Association of Pharmaceutical Professionals (SwAPP) and the Swiss Society for Pharmaceutical Medicine (SGPM) have accredited this training course with 32 credits.

Published 18 December 2015